ReviewCurrent hypertension reports2017
Relevance of microRNA 21 in Different Types of Hypertension.
Review in Current hypertension reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The Association of Micro-RNA 21 and Hypertension: A Meta-Analysis.Global heart · 2024Pooled it
- Pooled it
- Cardioprotective and Anti-Hypertensive Effects of Epigallocatechin Gallate: Novel Insights Into Biological Evidence.Journal of clinical hypertension (Greenwich, Conn.) · 2025Review
- Identification of potential shared gene signatures between periodontitis and breast cancer by integrating bulk RNA-seq and scRNA-seq data.Scientific reports · 2025Article
- Role of Gut Microbes in Hypertension: A Systematic Review of Literature.Annals of vascular diseases · 2025Review
- The clinical significance of T-cell regulation in hypertension treatment.Frontiers in immunology · 2025Review
- DAE-CFR: detecting microRNA-disease associations using deep autoencoder and combined feature representation.BMC bioinformatics · 2024Article
- Article
- Targeting intestinal microecology: potential intervention strategies of traditional Chinese medicine for managing hypertension.Frontiers in pharmacology · 2023Review
- β‑aminoisobutyric acid ameliorates hypertensive vascular remodeling via activating the AMPK/SIRT1 pathway in VSMCs.Bioengineered · 2022Article
- Clinical Significance of miR-21-5p in Predicting Occurrence and Progression of Uremic Vascular Calcification in Patients with End-Stage Renal Disease.Yonsei medical journal · 2022Article
- Extracellular Vesicle-Mediated Vascular Cell Communications in Hypertension: Mechanism Insights and Therapeutic Potential of ncRNAs.Cardiovascular drugs and therapy · 2022Review
- Circulating miRNA-21 as a diagnostic biomarker in elderly patients with type 2 cardiorenal syndrome.Scientific reports · 2020Article
- Review
- MicroRNA Expression Profiling of Bone Marrow-Derived Proangiogenic Cells (PACs) in a Mouse Model of Hindlimb Ischemia: Modulation by Classical Cardiovascular Risk Factors.Frontiers in genetics · 2020Article
- Circular RNA: a new biomarker for different types of hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2019Article
- Noncoding RNAs in Hypertension.Hypertension (Dallas, Tex. : 1979) · 2019Review
- Epigenetic Biomarkers in Cardiovascular Diseases.Frontiers in genetics · 2019Review
- Differential expression of MicroRNA let-7e and 296-5p in plasma of Egyptian patients with essential hypertension.Heliyon · 2018Article
- Noncoding RNAs in the Regulatory Network of Hypertension.Hypertension (Dallas, Tex. : 1979) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension (HTN) is a chronic medical condition that commonly affects the aging population worldwide. The prevalence of HTN is increasing in developing countries and is one of the leading causes of death in older individuals. HTN results from a complex interplay of genetic and environmental factors. Besides, HTN can result in various other health complications such as stroke and chronic kidney diseases, if not treated. Although various studies have explained the underlying mechanisms in the pathogenesis of HTN, limited information is available on their biomarkers. MicroRNAs (miRNAs) are RNA molecules that have been recognized as key regulators for HTN. miR-21 is a common microRNA that is has been reported to be significantly upregulated in HTN individuals. Hence, miR-21 can be a potential therapeutic target for HTN. The number of studies related to miR-21 on hypertension is limited. Therefore, the main thrust of this paper is to provide an overview of the current clinical evidence and significance of miR-21 in HTN.
Indexed as
Identifiers
28597404What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.